Quetiapine
- Generic Name
- Quetiapine
- Brand Names
- Seroquel
- Drug Type
- Small Molecule
- Chemical Formula
- C21H25N3O2S
- CAS Number
- 111974-69-7
- Unique Ingredient Identifier
- BGL0JSY5SI
- Background
Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable option for some patients with high sensitivity to other drugs, such as Clozapine and Olanzapine.
- Indication
Quetiapine is used in the symptomatic treatment of schizophrenia. In addition, it may be used for the management of acute manic or mixed episodes in patients with bipolar I disorder, as a monotherapy or combined with other drugs. It may be used to manage depressive episodes in bipolar disorder. In addition to the above indications, quetiapine is used in combination with antidepressant drugs for the treatment of major depression.
Some off-label uses for this drug include the management of post-traumatic stress disorder (PTSD), generalized anxiety disorder, and psychosis associated with Parkinson's disease.
- Associated Conditions
- Bipolar 1 Disorder, Depressive Episodes, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Mixed manic depressive episode, Post Traumatic Stress Disorder (PTSD), Psychosis, Schizophrenia, Acute Manic episode
Lithium Versus Quetiapine in Treatment Resistant Depression
- First Posted Date
- 2016-12-29
- Last Posted Date
- 2021-03-05
- Lead Sponsor
- King's College London
- Target Recruit Count
- 276
- Registration Number
- NCT03004521
- Locations
- 🇬🇧
Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom
Pharmacokinetics of Quetiapine Across Pregnancy and Postpartum
- First Posted Date
- 2016-12-01
- Last Posted Date
- 2022-09-27
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 4
- Registration Number
- NCT02978534
- Locations
- 🇺🇸
Northwestern Memorial Hospital, Chicago, Illinois, United States
Study Investigating the Effect of Lu AF35700 on Cardiac Repolarization in Men and Women With Schizophrenia and Schizoaffective Disorder
- Conditions
- SchizophreniaSchizoaffective Disorder
- Interventions
- First Posted Date
- 2016-09-15
- Last Posted Date
- 2019-09-12
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 119
- Registration Number
- NCT02901587
- Locations
- 🇺🇸
US1104, Long Beach, California, United States
Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies
- Conditions
- Bipolar Disorder
- First Posted Date
- 2016-09-08
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- University of New Mexico
- Target Recruit Count
- 1037352
- Registration Number
- NCT02893371
- Locations
- 🇺🇸
Christophe G Lambert, Albuquerque, New Mexico, United States
Treatment With Quetiapine for Youth With Substance Use Disorders and Severe Mood Dysregulation
- Conditions
- Substance Use DisordersBipolar DisorderMood Disorders
- Interventions
- Other: Placebo
- First Posted Date
- 2016-07-27
- Last Posted Date
- 2022-05-11
- Lead Sponsor
- Boston Medical Center
- Target Recruit Count
- 24
- Registration Number
- NCT02845453
- Locations
- 🇺🇸
Boston Medical Center, Boston, Massachusetts, United States
Levomilnacipran ER vs. Adjunctive Quetiapine for Adults With Inadequate Relief With SSRIs in MDD
- Conditions
- Major Depressive Disorder
- Interventions
- First Posted Date
- 2016-03-25
- Last Posted Date
- 2019-08-14
- Lead Sponsor
- Duke University
- Target Recruit Count
- 60
- Registration Number
- NCT02720198
- Locations
- 🇺🇸
Institute for Advanced Medical Research, Alpharetta, Georgia, United States
The Role of miR-30 Family Dysregulation in Response to Antipsychotic Treatment
- Conditions
- Schizophrenia
- Interventions
- First Posted Date
- 2016-01-08
- Last Posted Date
- 2016-01-08
- Lead Sponsor
- Shanxi Medical University
- Target Recruit Count
- 200
- Registration Number
- NCT02650102
- Locations
- 🇨🇳
First Clinical Medical College of Shanxi Medical University, Taiyuan, Shanxi, China
Quetiapine for Delirium Prophylaxis in High-risk Critically Ill Patients
- First Posted Date
- 2015-11-24
- Last Posted Date
- 2015-11-24
- Lead Sponsor
- University of Tennessee Graduate School of Medicine
- Target Recruit Count
- 82
- Registration Number
- NCT02612948
- Locations
- 🇺🇸
University of Tennessee Medical Center, Knoxville, Tennessee, United States
Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)
- Conditions
- Schizophrenia
- Interventions
- Other: Caregiver psycho-education and skills trainingOther: Caregiver support available at the study site
- First Posted Date
- 2015-11-09
- Last Posted Date
- 2019-01-23
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 296
- Registration Number
- NCT02600741
Clozapine Versus Other Atypical Antipsychotics for Bipolar Disorder
- Conditions
- Bipolar Disorder
- Interventions
- First Posted Date
- 2015-09-29
- Last Posted Date
- 2018-10-02
- Lead Sponsor
- Hospital de Clinicas de Porto Alegre
- Target Recruit Count
- 54
- Registration Number
- NCT02562287
- Locations
- 🇧🇷
Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.